Advertisement

Topics

Amgen drops two-brand Avastin biosimilar strategy in Europe

06:07 EST 14 Nov 2017 | BioPharma-Reporter

Mvasi has been recommended for approval in Europe, but a duplicate marketing authorisation application for an Avastin (bevacizumab) biosimilar has been withdrawn by Amgen.

Original Article: Amgen drops two-brand Avastin biosimilar strategy in Europe

NEXT ARTICLE

More From BioPortfolio on "Amgen drops two-brand Avastin biosimilar strategy in Europe"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...